Health
Pfizer/BioNTech COVID-19 vaccine continues to show strong effect in early-stage study – Seeking Alpha
Data from an ongoing Phase 1/2 clinical trial evaluating three dose levels of Pfizer (NYSE:PFE) and collaboration partner BioNTech SE’s (NASDAQ:BNTX) COVID-19 vaccine candidate BNT162b1 in healthy volunteers showed an acceptable safety profile and dose-depend…
Data from an ongoing Phase 1/2 clinical trial evaluating three dose levels of Pfizer (NYSE:PFE) and collaboration partner BioNTech SE’s (NASDAQ:BNTX) COVID-19 vaccine candidate BNT162b1 in healthy volunteers showed an acceptable safety profile and dose-dependent increases in glycoprotein receptor-binding domain (RBD)-binding IgG concentrations and SARS-CoV-2 neutralizing antibody titers. The data, just published in the journal Nature, was generated on the first two dose levels, 10 µg and 30 µg. …
-
General22 hours agoDairy farmers devastated by floods across parts of New South Wales
-
Noosa News19 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
Noosa News22 hours agoMan dies in Gold Coast after rolling trailer pins him to lamp-post
-
General18 hours agoSussan Ley’s office says Bridget McKenzie made false claims about cabinet solidarity